In summary, we found that ATP1A3 might be a potential target of CS‐6 in GBM and that regulating ATP1A3 could significantly impact the anti‐glioma efficacy of CS‐6 and its combination with TMZ. This evidence concerns the gene ATP1A3 and glioblastoma.